CM
VTGN icon

Caption Management’s VistaGen Therapeutics VTGN Stock Holding History

Caption Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$148K – 2088
2024
Q4 		$148K Hold
50,000
– – ﹤0.01% 1311
2024
Q3 		$151K Buy
+50,000
New +$171K ﹤0.01% 1093

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caption Management's VTGN Position: Q2 2026 in Review

Caption Management sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 14,664 shares — an estimated $8.38K sold.

Caption Management first reported a position in VTGN in Q2 2022 and held it in 6 quarters. The position peaked at $297K in Q2 2022. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Caption Management reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caption Management sold 14,664 VistaGen Therapeutics shares in Q2 2026, an estimated $8.38K.
  • Caption Management first reported a position in VistaGen Therapeutics in Q2 2022 and held it in 6 quarters.
  • Caption Management's VistaGen Therapeutics position peaked at $297K in Q2 2022.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.